halama_immunoDec 11
Cellular therapies have changed #immunooncology (IO) dramatically but their clinical and technical challenges in remain. Marco Donia (DK) elegantly summarized the developments and puts cutting-edge strategies on show at #ESMOimmuno25 in London. Careful patient selection is a decisive step to identify the patients who can benefit. This leads to impressive clinical results. So the role of systematic evaluation of IO-Biomarkers is paramount. #immunotherapy #immunology #Science #health
jobRxivNov 17

Research Director - Oncology
Private Health Management

Join PHM as a Research Director to lead cancer case research, guide treatment decisions, and transform patient care through precision medicine.

See the full job description on jobRxiv: https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/

#cancerresearch #ImmunoOncology #NeuroOncology #oncology #precisiononcol...
https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/?fsp_sid=5506

Research Director - Oncology

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
Yonhap Infomax NewsNov 5
Celltrion and Abpro will present preclinical data on their multispecific antibody cancer therapy CT-P72/ABP-102 at SITC 2025, targeting IND submission this year and first-in-human trials in 2025, after demonstrating strong efficacy and safety in preclinical studies.
#YonhapInfomax #Celltrion #Abpro #CTP72ABP102 #SITC2025 #ImmunoOncology #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89243
Yonhap Infomax NewsOct 31
Celltrion has signed a joint R&D deal with MustBio to co-develop a triple fusion immuno-oncology drug, securing global rights in a contract worth up to 712.5 billion won ($525 million).
#YonhapInfomax #Celltrion #MustBio #ImmunoOncology #TripleFusionProtein #7125BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88603
Celltrion Signs Joint R&D Agreement with MustBio for Multi-Antibody Immuno-Oncology Drug

Celltrion has signed a joint R&D deal with MustBio to co-develop a triple fusion immuno-oncology drug, securing global rights in a contract worth up to 712.5 billion won ($525 million).

Yonhap Infomax
jobRxivOct 25

Research Director - Oncology
Private Health Management

Join PHM as a Research Director to lead cancer case research, guide treatment decisions, and transform patient care through precision medicine.

See the full job description on jobRxiv: https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/

#cancerresearch #ImmunoOncology #NeuroOncology #oncology #precisiononcol...
https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/?fsp_sid=4470

Research Director - Oncology

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
jobRxivSep 9, 2025

Research Director - Oncology
Private Health Management

Join PHM as a Research Director to lead cancer case research, guide treatment decisions, and transform patient care through precision medicine.

See the full job description on jobRxiv: https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/

#cancerresearch #ImmunoOncology #NeuroOncology #oncology #precisiononcol...
https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/?fsp_sid=2286

Research Director - Oncology

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
jobRxivAug 21, 2025

Research Director - Oncology
Private Health Management

Join PHM as a Research Director to lead cancer case research, guide treatment decisions, and transform patient care through precision medicine.

See the full job description on jobRxiv: https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/

#cancerresearch #ImmunoOncology #NeuroOncology #oncology #precisiononcol...
https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/?fsp_sid=1397

Research Director - Oncology

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
jobRxivAug 9, 2025

Research Director - Oncology
Private Health Management

Join PHM as a Research Director to lead cancer case research, guide treatment decisions, and transform patient care through precision medicine.

See the full job description on jobRxiv: https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/

#cancerresearch #ImmunoOncology #NeuroOncology #oncology #precisiononcolo...
https://jobrxiv.org/job/private-health-management-27778-research-director-oncology/?fsp_sid=823

Research Director - Oncology

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
ScienceOpenJul 28, 2025

'Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy' - a Cancer Biology & Medicine (CBM) article on #ScienceOpen:

🔗 https://www.scienceopen.com/document?vid=49b8b5db-8b7e-4c37-b6e4-1139b82f6b93

#Oncology #HIVMedicine #Lymphoma #ImmunoOncology #CellTherapy

Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy

ScienceOpen
Yonhap Infomax NewsJun 2, 2025
GI Innovation is set to sign South Korea’s first immuno-oncology technology licensing deal with Merck, potentially marking a milestone for the domestic biotech sector as talks near completion for GI-101 and GI-102 combination with Keytruda.
#YonhapInfomax #GIInnovation #Merck #ImmunoOncology #Keytruda #TechnologyTransfer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65767
GI Innovation Nears Major Licensing Deal With Pharma Giant Merck

GI Innovation is set to sign South Korea’s first immuno-oncology technology licensing deal with Merck, potentially marking a milestone for the domestic biotech sector as talks near completion for GI-101 and GI-102 combination with Keytruda.

Yonhap Infomax